| | Variables | |
| | Males, n (%) | 34/57 (59.7) | | Median (IQR) age, years | 31 (24–47) |
| | Treatment outcome | | Median (IQR) annual expenditure/patient (euro) | 9073 (3661–14600) | | Median (IQR) drug dispensing number | 22 (8–34) | | Median (IQR) EASI at baseline | 31 (25–40) | | Median (IQR) EASI at the end of treatment | 5 (1–10) | | Median (IQR) delta EASI (%) | 86.8 (75–96) | | Median (IQR) DLQI at baseline | 10 (10–25) | | Median (IQR) DLQI at the end of treatment | 3 (1–5) | | Median (IQR) delta DLQI (%) | 80 (70–90) | | Median (IQR) NRS at baseline | 10 (8–10) | | Median (IQR) NRS at the end of treatment | 2 (1–3) | | Median (IQR) delta NRS (%) | 80 (70–90) | | Monotherapy, n (%) | 44/56 (78.6) |
| | Comorbidities | | None, n (%) | 17/57 (29.8) | | Allergic asthma, n (%) | 31/57 (54.4) | | Allergic rhinitis and/or conjunctivitis, n (%) | 15/57 (26.3) | | Bacterial skin infections, n (%) | 4/57 (7.0) | | Recurrent herpetic infections, n (%) | 2/57 (3.5) | | Neuropsychiatric diseases, n (%) | 0/57 (0.0) |
| | Affected areas | | Face/neck, n (%) | 48/57 (84.2) | | Body, n (%) | 3/57 (5.3) | | Genitals, n (%) | 28/57 (49.1) | | Hands, n (%) | 42/57 (73.7) |
| | Previous treatment | | Topical corticosteroids, n (%) | 52/57 (91.2) | | Topical immunomodulators (e.g., tacrolimus, pimecrolimus), n (%) | 26/57 (45.6) | | Systemic corticosteroids, n (%) | 26/57 (45.6) | | Cyclosporine, n (%) | 25/57 (43.9) | | Methotrexate, n (%) | 1/57 (1.8) | | Azathioprine, n (%) | 0/57 (0.0) | | NB-UVB phototherapy, n (%) | 1/57 (1.8) | | UVA1 phototherapy, n (%) | 0/57 (0.09) | | PUVA phototherapy, n (%) | 1/57 (1.8) |
|
|
